FLNA Filana Therapeutics, Inc.
Healthcare$1.31+1.55%ClosedMarket Cap: $63.3M
As of 2026-05-25
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.93
P/S
0.00
EV/EBITDA
0.29
DCF Value
$1.85
FCF Yield
-141.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-99.8%
ROA
-71.9%
ROIC
-120.1%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 null | $0.00 | $-10.3M | $— |
| Q4 null | $0.00 | $-12.5M | $— |
| FY null | $0.00 | $-91.0M | $— |
| Q3 null | $0.00 | $-10.8M | $— |
Analyst Ratings
View AllConsensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
0 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
-0.76
Filana Therapeutics, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.